Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Cancer Predisposition
•
BRCA+
•
Breast Cancer, Non-metastatic
Is it safe to use hormone replacement therapy in young premenopausal patients with BRCA1 mutation, triple negative breast cancer, who have undergone bilateral mastectomies and BSO without hysterectomy?
Related Questions
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
Would you offer adjuvant olaparib to a male patient with HR+, HER2- T2N0 breast cancer with a BRCA2 germline mutation following mastectomy who is not a candidate for adjuvant chemotherapy?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Is there an increaed risk of cancer when using spironolactone in patients with hormone positive breast cancer?
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
In which patients do you offer adjuvant bisphosphates in breast cancer treatment?
What adjuvant systemic therapy would you give a patient with ER+/HER2- breast cancer s/p mastectomy, chemo (TC), 5 years of endocrine therapy who presents with nodal recurrence s/p ALND showing 4 involved nodes?
What would you recommend regarding IVF in a patient with DCIS on tamoxifen dealing with infertility?”
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?